Biofrontera Inc. Names Gerard DiGirolamo as National Sales Director

WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the appointment of Gerard DiGirolamo as National Sales Director. In this newly created position, Mr. DiGirolamo will report to Mark Baldyga, Biofrontera's Head of Sales & Marketing, and will help execute the Company's U.S. sales division and objectives including the strategic design, expansion and leadership of its sales team. He will oversee recruiting and staffing to support Ameluz®, BF-RhodoLED® and Xepi® commercial efforts, as well as spearhead planning for the launch of BF-RhodoLED XL®.

Mr. DiGirolamo brings to Biofrontera more than 25 years of experience in building pharmaceutical sales and commercial teams with a particular expertise in dermatology. Most recently he served as Vice President of Sales at Verrica Pharmaceuticals, a medical dermatology company where he built their U.S. sales infrastructure in preparation for a commercial launch of its drug-device combination product for the treatment of molluscum contagiosum. This provides valuable experience for working with Biofrontera's combination of Ameluz® and the RhodoLED® lamps.

"Gerard's insight and understanding of the dermatology market, along with the many relationships he's cultivated within our industry will be extremely valuable in working with Mark Baldyga on the successful implementation of our commercial strategy. His approach involving collaborating with medical affairs, marketing, key opinion leaders and national influencers through advisory boards and conferences fully aligns with our mission. He is passionate about building cohesive and collaborative teams that have led to successful product launches and market-share gains. We are delighted to have Gerard lead our commercial team and welcome him to Biofrontera," stated Erica Monaco, Chief Executive Officer of Biofrontera Inc.

"I'm proud to join Biofrontera and to support their commitment to dermatological innovation. With my experience in building and supporting teams at national and regional levels, I look forward to leveraging my networks to position Ameluz-PDT as the first-choice treatment for actinic keratosis and establishing the optimal commercial infrastructure for a successful launch of BF-RhodoLED XL®," stated Mr. DiGirolamo.

Prior to Verrica Pharmaceuticals, Mr. DiGirolamo was a Field Vice President at GlaxoSmithKline (GSK) and previously spent 16 years with Stiefel, now part of GSK. At GSK he worked with multiple dermatology brands and exceeded sales forecasts including for the launch of Fabior Foam®, a treatment for psoriasis and acne. As Executive National Account Manager at Stiefel he led negotiations with national managed care organizations, securing

unrestricted access to the acne therapy Duac CS™ and coverage of the seborrheic dermatitis therapies Extina™ and Xologel™. Prior to Stiefel, he was an Area and District Sales Manager at Novartis. Mr. DiGirolamo holds a B.A. from Rutgers University.

About Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the Company's business and marketing strategy, future operations and business, potential to expand the label of Ameluz®, market presence and position of Ameluz® and ongoing clinical trials conducted by our licensing partners and the future impact of such trials on the market for Ameluz®. We have based these forward-looking statements on our current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, including, but not limited to, the impact of extraordinary external events, such as the current COVID-19 pandemic; any changes in the Company's relationship with its licensors; the ability of the Company's licensors to fulfill their obligations to the Company in a timely manner; the Company's ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company's ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company's licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz® in combination with BF-RhodoLED® in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz® in combination with BF-RhodoLED® is consistent with the Company's expectations; the Company's ability to complete the transition to a public company; the Company's ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing and other factors that may

be disclosed in the Company's filings with the SEC, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

Contacts:

Biofrontera Inc.
Anke zur Mühlen
+1 781 486 1539
us-ir@biofrontera.com

LHA Investor Relations
Tirth T. Patel
+1 212 201 6614
tpatel@lhai.com

# # #